Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines
Combined Measles, Mumps, Rubella, Varicella Vaccine
Measles; Mumps; Rubella; Varicella
Phase 3
This is a Year 2 follow up study to 208136/038. An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
February 2015